sonesitatug vedotin

all catalysts(0)

nothing on the calendar yet

News(3)

• FDA scientists question Capricor data; Legend CEO steps down
  Capricor shares lost much of their value ahead of a high-stakes advisory committee meeting. Elsewhere, Ying Huang’s resignation extended a stock slide for Legend and AstraZeneca disclosed more pipe…
  biopharma_dive · 15d ago
• AstraZeneca has no plans to ramp up dealmaking in wake of Wainua failure
  AstraZeneca remains "very much on track" to hit its 2030 goal of reaching $80 billion in revenue despite the recent late-stage failure of Wainua in ATTR-cardiomyopathy, CEO Pascal Soriot said durin…
  biospace · 15d ago
• AstraZeneca execs ‘very confident’ in homegrown ADC pipeline despite scrapping 2 candidates
  AstraZeneca executives told Fierce they are “very confident” in the pharma’s in-house pipeline of ADCs despite scrapping two candidates that underperformed in the clinic.
  fiercebiotech · 15d ago